logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Incyte Corporation Skyrockets on Promising Trial for Jakafi

  +Follow August 21, 2013 9:20AM
Share:
Tickers Mentioned:

Pharmaceutical company Incyte Corporation (INCY) released very positive news on Aug. 21, revealing that their pancreatic cancer treatment drug ruxolitinib, marketed under the trade name Jakafi, had performed very well in Phase II trials, and that the drug could now move on to Phase III.

Incyte Executive Vice President Richard S. Levy pointed out that sufferers from advanced pancreatic cancer currently have very few options. If approved, the orally-administered drug would be one of the first on the market that exists as "an attractive treatment option" for sufferers of pancreatic cancer.

If approved by the FDA, this would be a major breakthrough. Metastatic pancreatic cancer has the lowest survival rate of any form of cancer. Currently, less than one percent of people afflicted survive more than five years.

Jakafi's ability to increase lifespan for sufferers looks very promising. In the Phase II trials, the six month survival rate for patients (when coupled with chemotherapy treatment) for Jakafi was 42 percent, compared to 11 percent for patients on a placebo.

Jakafi was first approved by the Food and Drug Administration in 2011 to treat a bone marrow disease. After its success in that arena, the company specualted that the drug might effectively treat other types of cancer as well. Now, the drug is fast aproaching approval to treat pancreatic cancer as well. Though it is currently the only drug the company has gotten passed by the USFDA. Jakafi seems to be fulfilling early analyst speculation that it could be a billion dollar blockbuster drug for the Delaware-based drug maker.

Incyte earned $54.1 million from sales of Jakafi in the second quarter of 2013, and expects to earn between $220 and $230 million total this year.

Incyte rocketed on the news, and went up 29.19 percent to hit $34.88 a share. They’re up 58.82 percent on the year.

(image courtesy of Wikimedia commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Signup for our daily newsletter and get our best articles emailed right to you!

Results for INCY
A P
24 Oct 14 15:47:40
$INCY Incyte to Present at the Nomura BioPharma Conference http://t.co/GkeIWzTKl0 #BiotechTraderHandbook--> http://t.co/JDdc1OTfZF
NASDAQ
24 Oct 14 13:19:39
$INCY - Statement of Changes in Beneficial Ownership (4) http://t.co/PWSur2vow9
$Stocknewsalerts
24 Oct 14 13:19:13
$INCY ALERT: New Incyte Corporation SEC Filing From our Stock News Alerts App
NASDAQ
24 Oct 14 13:17:24
$INCY - Statement of Changes in Beneficial Ownership (4) http://t.co/9LD09ecaYO
Market Int Center
24 Oct 14 10:41:44
Incyte $INCY Trading Near $56.93 Resistance Level ( http://t.co/FR2oEzC7Wd )
Irma Doucet
24 Oct 14 08:31:41
$INCY Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma ... http://t.co/PcezxZqWIa
Jeffrey Blake
24 Oct 14 08:31:39
$INCY Incyte to Present at the Nomura BioPharma Conference http://t.co/tfhFabwEiG
stockblaster14
23 Oct 14 23:44:33
Incyte Corp (INCY) 54.95 $INCY Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Dr http://t.co/lcl8cHPykq
Luke Lee
23 Oct 14 22:36:43
Thoughts on who would pay $10B+ for $INCY and $MDVN? http://t.co/FsSg6yOkrG
Luke Lee
23 Oct 14 22:32:48
RT @JacobEPVantage: UBS sees an optimistic read-across to $INCY of the $RHHBY $NLNK IDO deal. http://t.co/P7VanZby4B
Luke Lee
23 Oct 14 22:32:02
RT @DrPaulyDeSantis: $INCY Jefferies: $NLNK $RHHBY IDO-1 deal Validates INCY's IDO-1 program already in development, data at ASCO 2015 with…
Luke Lee
23 Oct 14 22:30:31
RT @bnkinvest: Incyte Breaks Above 200-Day Moving Average - Bullish for $INCY $FBT #stocks http://t.co/rRYUbmRucY
12Stocks.com
23 Oct 14 16:04:26
MidCap #Stocks Trend $UFS $KMX $ORLY $FEYE $INCY $CBST $LEG $SFG $CVI $GCI $AAL $DRQ $RLGY $HLF $BSX $PKG @ http://t.co/tf79gD96D3
The GMP Group
23 Oct 14 13:35:04
RT @fwpharma: ViewPoints: Roche says 'IDO' to NewLink; Incyte left in the dating game? http://t.co/4h5XtKfQ8U $RHHBY $NLNK $INCY #oncology
FirstWord Pharma
23 Oct 14 13:30:17
ViewPoints: Roche says 'IDO' to NewLink; Incyte left in the dating game? http://t.co/4h5XtKfQ8U $RHHBY $NLNK $INCY #oncology
BNK Invest
23 Oct 14 13:29:12
Incyte Breaks Above 200-Day Moving Average - Bullish for $INCY $FBT #stocks http://t.co/rRYUbmRucY
12Stocks.com
23 Oct 14 13:00:58
MidCap #Stocks Trend $KMX $ORLY $FEYE $LEG $CVI $RLGY $INCY $DRQ $GCI $IHS $CBST $PKG $HLF $PLL $WAT $PHM @ http://t.co/H27z0JgFGk
Media Sentiment
23 Oct 14 12:44:50
$INCY received a new alert. Find out why at http://t.co/nZwqRf3BRT #stocks #daytrading #trading #mkt #NYSE #NASDAQ #markets 653
Market Int Center
23 Oct 14 12:41:54
Incyte $INCY Showing Bullish Technicals With Resistance At $54.34 ( http://t.co/v01pCBChv5 )
Vincent
23 Oct 14 12:26:19
earlier today so1d to c1ose 5 $INCY Nov $55 Call @ 1.85 from 1.63 and so1d to c1ose 2 Dec $55 Call @ 3.80 from 2.50.
fezziwig2008
23 Oct 14 12:19:32
@FinansciCenk $INCY traded up 30% on 42% 6 mo survival- another way of saying Median Overall Surv less than 6 Mos- $HALO 3x that in Ph1b
fezziwig2008
23 Oct 14 12:00:23
$INCY trading @ $55 right now in part on Jakafi MOS in Panc Ca under 6 months- PegpH20 extended MOS to 19mos. $HALO
Penny Stock Secret
23 Oct 14 10:21:25
The Hottest Way to Make Millions From Stock Market.Click HERE http://t.co/SVqoMkrw2z .. $BOSC $INCY $SHLD
DR.THOMPSON
23 Oct 14 10:00:10
Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales http://t.co/tpAzXBOcrc $LLY just buy $INCY........
zach
23 Oct 14 09:20:38
$INCY baracitinib pIII data may slip into '15 says $LLY
scott
23 Oct 14 08:43:24
RT @portefeuillefun: Want to buy NAV ≈ $268.5 for ≈ $200? For a portfolio mostly made up of $CELG $GILD $ATLN $ISIS $INCY ...-> #BBBiotech …
Eternity101
23 Oct 14 08:42:50
RT @tymorapro: $INCY: 1mRunaway+:1 [+3%,.2%offHi], allTFs+; TLM:1.3; ILM:1.2, PrvClGap+[+1.0%], 1MoHi+, DyVol:249T:0.5x:0.2x, DyRng:3%:0.8x…
Alexander Morris
23 Oct 14 08:38:03
$INCY: 1mRunaway+:1 [+3%,.2%offHi], allTFs+; TLM:1.3; ILM:1.2, PrvClGap+[+1.0%], 1MoHi+, DyVol:249T:0.5x:0.2x, DyRng:3%:0.8x:0.7x,
V.S. Schulz
23 Oct 14 08:25:05
Want to buy NAV ≈ $268.5 for ≈ $200? For a portfolio mostly made up of $CELG $GILD $ATLN $ISIS $INCY ...-> #BBBiotech http://t.co/wzgNbv6jbd
fezziwig2008
23 Oct 14 06:53:57
$INCY Rose 30% on "Inc MOS w no Inc PFS in Panc Ca" $HALO Increased Gem's MOS 200% & PFS 100% http://t.co/DXvrzxYs0z http://t.co/41BGc1WO7c
Stock Moo
23 Oct 14 05:55:15
$incy: Incyte to Present at the Nomura BioPharma Conference http://t.co/uGIHbH1Bhp
$Stocknewsalerts
23 Oct 14 05:03:05
$INCY Incyte to Present at the Nomura BioPharma Conference From our Stock News Alerts App
BV Healthcare
23 Oct 14 05:00:17
$INCY Incyte to Present at the Nomura BioPharma Conference.. http://t.co/aQW4xwqAnP
Joe
23 Oct 14 03:43:29
RT @lomu_j: $LLY $INCY Top line Baricitinib in RA late 2014 or early 2015 per Lilly 3Q14 update
j l
23 Oct 14 03:35:32
$LLY $INCY Top line Baricitinib in RA late 2014 or early 2015 per Lilly 3Q14 update
wininstocks2014
22 Oct 14 18:37:05
INCY 52.47 Stock Charts $INCY Incyte Corp. (NASDAQ) Last Updated: 10/22/2014 20:37:04 INCY Stock Chart - 1 Mon http://t.co/yibLvCLjoj
Daily Contracts
22 Oct 14 13:37:01
Real-Time feed of company contracts, original agreements and executive updates from Incyte Corporation $INCY http://t.co/KBicQORxY2
Samuel Brown
22 Oct 14 12:01:34
$INCY Incyte Appoints David Gryska as Executive Vice President and Chief Financial ... http://t.co/az8ZHjUutZ
Vincent
22 Oct 14 10:06:15
so1d to c1ose 4 of 9 $INCY Nov $55 Call @ 2.05 from 1.63 for approx +25%.
The GMP Group
22 Oct 14 04:04:32
RT @fwpharma: ViewPoints: Roche says 'IDO' to NewLink; Incyte left in the dating game? http://t.co/4h5XtKfQ8U $RHHBY $NLNK $INCY #oncology
FirstWord Pharma
22 Oct 14 04:00:57
ViewPoints: Roche says 'IDO' to NewLink; Incyte left in the dating game? http://t.co/4h5XtKfQ8U $RHHBY $NLNK $INCY #oncology
Влад
21 Oct 14 20:03:50
RT @AndyBiotech: $STML New Study of SL-401(Anti-CD123 conjugate) in High Risk Myeloproliferative Neoplasms at Mayo Clinic http://t.co/TEXRn…
TipRanks
21 Oct 14 18:34:31
4-star analyst Thomas Wei from Jefferies reiterated a BUY rating on $INCY. http://t.co/utufiIA0NZ #NASDAQ #stocks
Andy Biotech
21 Oct 14 11:39:35
$STML New Study of SL-401(Anti-CD123 conjugate) in High Risk Myeloproliferative Neoplasms at Mayo Clinic http://t.co/TEXRnTAn8C $GERN $INCY
zach
21 Oct 14 08:37:35
BAR call - genentech said wanted their own IDO compound, didn't like the uncertain path fwd w $INCY IDO, said $NLNK deal was v competitive
Jacob Plieth
21 Oct 14 03:23:25
SanRx $NLNK $INCY RT @DatamonitorMark: They’ve been following this line of thinking for a few years: http://t.co/fVgfW0w0js
Jacob Plieth
21 Oct 14 03:04:17
How about that? SanRx says it's selling an IDO inhibitor as a dietary supplement http://t.co/lfi3tiNyOQ $NLNK $INCY $RHHBY
12Stocks.com
21 Oct 14 03:03:32
Weekly MidCap #Stocks Trend $SHLD $TMHC $NSM $ARIA $OCN $LII $LEN $DPZ $DHI $PHM $FEYE $THRX $INCY $ADS $ALK @ http://t.co/tf79gD96D3
Dr. Paul DeSantis
20 Oct 14 23:25:15
$INCY Jefferies: $NLNK $RHHBY IDO-1 deal Validates INCY's IDO-1 program already in development, data at ASCO 2015 with $MRK Keytruda
Luke Lee
20 Oct 14 22:30:43
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
				
				
  +Follow August 21, 2013 9:20AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.